“…We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. PATIENTS AND METHODS: We performed a retrospective study on AIH patients with COVID-19. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…MÉTODOS: Ensayo clínico (NCT05246137) de fase III, abierto, no-controlado y multicéntrico en una cohorte de voluntarios (≥ 16 años) vacunados con AstraZeneca, Janssen, Pfizer-BioNTec o Moderna al menos 3 meses antes de la administración de una dosis de refuerzo con la vacuna de proteína recombinante PHH-1V (basada en las variantes Alfa y Beta). …”
Enlace del recurso
Enlace del recurso

“…|Janssen: Stocks/Bonds Marc Bonten, MD, PhD, Astra-Zeneca: Advisor/Consultant|Janssen: Advisor/Consultant|Merck: Advisor/Consultant|Novartis: Advisor/Consultant.…”
Enlace del recurso
Enlace del recurso

“…Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. …”
Enlace del recurso
Enlace del recurso

“…[Figure: see text] DISCLOSURES: Timothy Burgess, MD, MPH, AstraZeneca: The HJF, in support of the USU IDCRP, was funded to conduct or augment unrelated Phase III Mab and vaccine trials as part of US Govt. …”
Enlace del recurso
Enlace del recurso

“…This study was funded by Sanofi and AstraZeneca. DISCLOSURES: Jason Gantenberg, PhD, MPH, Sanofi: Grant/Research Support Robertus van Aalst, PhD, MSc, Sanofi: Stocks/Bonds David R. …”
Enlace del recurso
Enlace del recurso

“…Pour les patients vaccinés (83 %), les vaccins administrés étaient les suivants : 63,6 % Pfizer BioNTech, 6,8 % AstraZeneca, 5,7 % Moderna, 4,5 % Johnson & Johnson, 2,3 % Sinovac-CoronaVac et 17 % non précisés. …”
Enlace del recurso
Enlace del recurso

“…Of the reported AEs, 38,309 (53. 6%) side-effects were reported following Pfizer-BioNTech, 32,223 (45%) following Oxford-AstraZeneca, and 948 (1.3%) following Moderna. The following reported AEs were statistically significant between the different vaccine types: shortness of breath\difficulty of breathing, dizziness, fever above 39°C, headache, hoarseness, injection site reactions, itchiness, nausea, sleep disruption, fatigue, wheezing, swelling of lips/face and\or throat, and loss of consciousness (p-value < 0.05). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Turtle, MBBS, PhD, Allogene: Advisor/Consultant|Allogene: Ad hoc advisory boards/consulting|ArsenalBio: Advisor/Consultant|ArsenalBio: Scientific Advisory Board, stock options|ArsenalBio: Stocks/Bonds|Caribou Biosciences: Advisor/Consultant|Caribou Biosciences: Stocks/Bonds|Century Therapeutics: Advisor/Consultant|Century Therapeutics: Ad hoc advisory boards/consulting|Eureka Therapeutics: Stocks/Bonds|Fred Hutchinson Cancer Center: CJT has the right to receive payment from Fred Hutchinson Cancer Center as an inventor on patents related to CAR-T-cell therapy|Juno Therapeutics/BMS: Grant/Research Support|Kyverna: DSMB member|Legend Bio: Advisor/Consultant|Legend Bio: Ad hoc advisory boards/consulting|Myeloid Therapeutics: Advisor/Consultant|Myeloid Therapeutics: Scientific Advisory Board, stock options|Myeloid Therapeutics: Stocks/Bonds|Nektar Therapeutics: Advisor/Consultant|Nektar Therapeutics: Grant/Research Support|Prescient Therapeutics: Advisor/Consultant|Prescient Therapeutics: Ad hoc advisory boards/consulting|Sobi: Advisor/Consultant|Sobi: Ad hoc advisory boards/consulting|Syncopation Life Sciences: Advisor/Consultant|Syncopation Life Sciences: Ad hoc advisory boards/consulting|T-CURX: Advisor/Consultant|T-CURX: Scientific advisory board Mazyar Shadman, MD, AbbVie: Advisor/Consultant|AbbVie: Grant/Research Support|ADC therapeutics: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|BeiGene: Advisor/Consultant|BeiGene: Grant/Research Support|BMS: Advisor/Consultant|BMS: Grant/Research Support|Eli Lilly: Advisor/Consultant|Fate Therapeutics: Advisor/Consultant|Genentech: Advisor/Consultant|Genentech: Grant/Research Support|Genmab: Advisor/Consultant|Genmab: Grant/Research Support|Kite: Advisor/Consultant|MorphoSys/Incyte: Advisor/Consultant|MorphoSys/Incyte: Grant/Research Support|Mustang Bio: Advisor/Consultant|Mustang Bio: Grant/Research Support|Nurix and MEI Pharma: Advisor/Consultant|Pharmacyclics: Advisor/Consultant|Pharmacyclics: Grant/Research Support|Regeneron: Advisor/Consultant|TG Therapeutics: Grant/Research Support|Vincerx: Grant/Research Support Brian Till, MD, Juno Therapeutics/BMS: Grant/Research Support|Mustang Bio: Grant/Research Support|Mustang Bio: patents/royalties|Mustang Bio: Consulting|Proteios Technology: Advisor/Consultant Ryan D. …”
Enlace del recurso
Enlace del recurso

“…Khodadoust:  CRISPR Therapeutics, Nutcracker Therapeutics: Research Funding; Myeloid Therapeutics: Membership on an entity's Board of Directors or advisory committees; Alexion, AstraZeneca Rare Disease: Other: Study investigator. …”
Enlace del recurso
Enlace del recurso

“…Serious adverse events (SAEs) mRNA‐1273, ChAdOx1 (Oxford‐AstraZeneca)/SII‐ChAdOx1 (Serum Institute of India), Ad26.COV2.S, and BBV152 probably result in little or no difference in SAEs compared to placebo (RR: mRNA‐1273: 0.92, 95% CI 0.78 to 1.08; 2 RCTs, 34,072 participants; ChAdOx1/SII‐ChAdOx1: 0.88, 95% CI 0.72 to 1.07; 7 RCTs, 58,182 participants; Ad26.COV2.S: 0.92, 95% CI 0.69 to 1.22; 1 RCT, 43,783 participants); BBV152: 0.65, 95% CI 0.43 to 0.97; 1 RCT, 25,928 participants). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…INTRODUCTION: The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…There were several vaccines that caused reactivation including BNT162b2 mRNA or Pfizer–BioNTech (n = 76), Oxford-AstraZeneca (n = 22), mRNA-1273 or Moderna (n = 17), Sinovac (n = 4), BBIBP-CorV or Sinopharm (n = 3), Covaxin (n = 3), Covishield (n = 3), and Johnson and Johnson (n = 1). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We included individuals who received two vaccine (primary) doses of the BNT162b2 mRNA (Pfizer-BioNTech) and two vaccine doses of ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our analyses. We carried out a self-controlled case series (SCCS) analysis for each outcome using a conditional Poisson regression model with an offset for the length of risk period. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Pedersen: Other; Self; AstraZeneca, Bausch, Eli Lilly & Company, Novo Nordisk, Jansen Pharmaceuticals, Boehringer Ingelheim, Sanofi, Merck, Abbott Laboratories, HLS, Bayer, Inc., Pfizer, Inc., Dexcom. …”
Enlace del recurso
Enlace del recurso

“…All but one of the participants were vaccinated against COVID-19, mostly Oxford-AstraZeneca (41.7%) and Pfizer-BioNTech (35.8%). Among those vaccinated, 64 (55.7%) reported on some adverse events, the most common pain at the site of vaccine shot (28.3%), fever (19.5%) and headache (9.7%), with a median duration of 1.5 days (range 1-3). …”
Enlace del recurso
Enlace del recurso

“…[Figure: see text] DISCLOSURES: Xavier Bourge, PharmD, Merck: Employe Brune Akrich, MD, MSD: Employee David Boutoille, MSD France: Board Member Isabelle Brassac, Scientist, MSD France: salary Carole Mackosso, n/a, MSD France: MSD employee Jean-François Timsit, MD, merck: Advisor/Consultant Bernard Castan, MD, ADVANZ: SPEAKER MODERATOR|BIOMERIEUX: SPEAKER MODERATOR|GILEAD: Advisor/Consultant|MSD France: Board Member|MSD France: SPEAKER MODERATOR|SANOFI: Advisor/Consultant|SHIONOGI: Advisor/Consultant Pierre-Regis Burgel, MD,PHD, ASTRA-ZENECA: Honoraria|BOEHRINGER INGELHEIM: Honoraria|CHIESI: Honoraria|GSK: Honoraria|INSMED: Honoraria|NOVARTIS: Honoraria|PFIZER: Honoraria|VERTEX: Grant/Research Support|ZAMBON: Honoraria…”
Enlace del recurso
Enlace del recurso

“…Fowler, MD, MHS, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, Astra Zeneca: Advisor/Consultant|Genentech, Regeneron, Deep Blue, Basilea, Janssen;: Grant/Research Support|Infectious Diseases Society of America: Honoraria|MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius;: Grant/Research Support|Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny,: Advisor/Consultant|Sepsis diagnostic: Patent pending|UpToDate: Royalties|Valanbio and ArcBio: Stock Options…”
Enlace del recurso
Enlace del recurso

“…Dubberke, MD, MSPH, Abbott: Advisor/Consultant|AstraZeneca: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Ferring Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Seres Therapeutics: Advisor/Consultant|Summit: Advisor/Consultant|Theriva Biologics: Grant/Research Support Qinghua Li, PhD, Merck & Co Inc: Employee Engels N. …”
Enlace del recurso
Enlace del recurso

“…Fowler, MD, MHS, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, Astra Zeneca: Advisor/Consultant|Genentech, Regeneron, Deep Blue, Basilea, Janssen;: Grant/Research Support|Infectious Diseases Society of America: Honoraria|MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius;: Grant/Research Support|Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny,: Advisor/Consultant|Sepsis diagnostic: Patent pending|UpToDate: Royalties|Valanbio and ArcBio: Stock Options Joshua T. …”
Enlace del recurso
Enlace del recurso